KRAS has long been one of the most important targets in oncology, and for decades it was widely considered “undruggable”. Fortunately, that perception has changed rapidly and today, KRAS-targeted therapies are no longer theoretical. They are clinically validated, increasingly effective, and reshaping how drug development programmes are designed.
The transition from early KRAS inhibitors (KRASi) to next-generation compounds represents a fundamental shift in how our field approaches targeted therapy. For preclinical and translational teams, this shift introduces both opportunity and risk. Programs that adapt quickly will be well positioned to succeed, whereas those that rely on outdated models and assumptions may fall behind.
A New Standard of Care Is Emerging
Recent clinical data for pan-RAS(ON) inhibitors, such as daraxonrasib, signal a turning point in KRAS drug development. As these therapies move toward becoming standard of care, they establish a new benchmark against which all future KRAS-directed agents will be measured.
This has immediate implications for preclinical strategies, and it is no longer sufficient to demonstrate activity in isolation. Every new therapy must now be evaluated relative to an evolving clinical reference point.
For companies developing therapies in KRAS-mutant indications such as non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic cancer, the key question has changed. It is no longer “Does this work?” but “Does this outperform or complement what already exists?”.
Why Traditional Preclinical Approaches Are No Longer Enough
Historically, KRAS drug development has relied heavily on simplified systems such as cell lines or limited in vivo studies. While these approaches played an important role in early discovery, they are insufficient for today’s demands.
KRAS biology is highly context dependent and mutation status alone does not determine response. Co-occurring genomic alterations, transcriptional programmes, and protein-level signalling all contribute to therapeutic sensitivity and resistance.
As a result, preclinical systems that lack clinical relevance or molecular depth fail to capture the complexity of real tumours. This creates a disconnect between preclinical findings and clinical outcomes, increasing the risk of late-stage failure.
The Role of Clinically Relevant Models
To address this challenge, there is a growing shift toward clinically relevant models such as patient-derived xenografts (PDXs) with integrated molecular characterisation. These models enable a deeper understanding of tumor biology and provide a more accurate representation of patient response.
Importantly, when these models are combined with longitudinal data and treatment history, they allow researchers to study both intrinsic sensitivity and acquired resistance. This is essential in KRAS, where resistance is not an exception but an expected outcome.
Benchmarking as the New Foundation
In this evolving landscape, benchmarking is becoming the basis of an effective preclinical strategy, and access to datasets that include response to current or emerging standards of care allow scientists to:
- Identify responder and non-responder populations
- Understand the molecular drivers of response
- Design rational combination strategies
- Prioritise assets with the highest likelihood of success
At Champions Oncology, we recognised that benchmarking would become essential in the KRAS space. Our work has focused on building clinically annotated datasets that connect tumor response directly to molecular biology. This enables a level of insight that extends far beyond traditional screening approaches.
From Activity to Decision-Making
The ultimate goal of preclinical research is not only to generate data, but to inform your decision making.
In KRAS drug development, the stakes are high. Clinical trials are expensive, timelines are long, and the competitive landscape is rapidly evolving. Preclinical data must therefore do more than demonstrate activity. It must guide:
- Patient selection strategies
- Combination therapy design
- Clinical trial structure
- Pipeline prioritisation
This requires a shift from descriptive models to more predictive, translational systems.
Looking Ahead
KRAS has entered a new era. The science is advancing, the clinical landscape is evolving, and expectations are rising across the industry.
For preclinical teams, this is a moment to reassess how studies are designed, how models are selected, and how data are interpreted. The organisations that lead in this space will be those that align their strategy with the realities of the current landscape, not the assumptions of the past.
In the next blog in this series, we explore why benchmarking is no longer optional in KRAS research and how it is reshaping preclinical decision-making.
